One more bispecific, humanized IgG1 antibody that may be below investigation is zenocutuzumab (MCLA-128), which functions via two independent mechanisms of motion: inhibition of HER2–HER3 signalling and elimination of tumour cells via ADCC. MCLA-128 features by using a ‘dock and block’ mechanism whereby one particular arm from the antibody binds https://www.directivepublications.org/journal-of-clinical-breast-cancer/